Ahuja Pulliam Montgomery

at2a Nattokinase 10,000 FU

There are 110 male adult film performers on my concierge medical roster. I see each one for a full comprehensive urological and vascular workup annually, with quarterly follow-up panels — semen analysis included — for the performers under long-term contract. I have followed many of the same men for over a decade. And what I have learned about why a man's ejaculate disappears — by watching them — is what I am about to tell you. 3 · ENGLISH BODY (Paste the chosen hook above, then everything below it, as one continuous primary text. No headline, no bold, no section breaks in the live ad.) My name is Dr. Warren Ashby. I am 51 years old. I trained at Johns Hopkins, completed my cardiology fellowship at UCLA in 2005, and have run a concierge medical practice in Beverly Hills for the last 11 years. My patient roster is small — under 200 active patients — and skewed toward entertainment industry clients who need confidential, accessible primary care that the standard medical system isn't designed to deliver. In 2015, a talent manager who represented several performers in adult film referred his first client to me. The performer had been declined by two standard physicians for a confidential workup — neither would see him without his name in their clinical record. He needed annual panels, occasional acute care, and the kind of medical relationship that didn't generate searchable records. I took him on. Within eighteen months, his agency had referred eleven more performers. Over the next several years, two adjacent agencies followed. Today, 110 of my 180 active patients are male adult film performers ranging in age from 24 to 61. The rest are entertainment, finance, and tech executives with similar privacy requirements. In the 11 years since, I have personally run comprehensive panels on each performer at least annually, often quarterly — flow rate, post-void residual, prostate volume on ultrasound, symptom scoring, fibrinogen, full lipids, and semen analysis. The longitudinal data I have on this population is unusual. Most physicians never get to track the same patient quarterly for 11 years. I have done it for 110 men whose ejaculatory load is the most extreme in the country. Let me explain what I mean. Adult film performance, in urological terms, is a stress test. A performer has to produce a full, visible, on-demand ejaculate in front of a camera, sometimes three and four times in a shooting day, sometimes on ninety minutes of recovery. Volume is the deliverable. It is not a private outcome — it is the shot. Around that: water cut for two days before a shoot to sharpen the camera. Testosterone and hCG cycles running through a good half of the roster. Hours of sustained pelvic engorgement, weeks on end. Ten hours sitting in a van between locations. Sleep on nobody's schedule. The load on a man's prostate, his ejaculatory ducts and the valve between them is closer to what a racehorse's tendons take in a season than anything a normal man's plumbing will ever see — except the season never ends. By every standard urology model, this lifestyle should produce an enlarged prostate, night-time urinary frequency, a collapsing stream and total ejaculatory volume loss by the late 40s. For the majority of performers, it does. But not all of them. 8% of male performers over 50 in my data still produce an ejaculate volume above 3.5 millilitres, with a symptom score under 4 and a peak flow over 20. That is not "acceptable for his age." That is the semen analysis and the flow study of a healthy 27-year-old. And it is being produced by men in their fifties who have put that specific system through more in one decade than you will in your entire life. Men who dehydrate on purpose. Men who don't sleep. Men who have been on and off hormones for twenty years. The load that should have put them on a prescription at 45 is producing the plumbing of a man half their age. The other 92% follow the expected trajectory. The symptom score climbs into the 8-to-19 range by their mid-40s. Peak flow drops under 15, then under 10. Post-void residual climbs past 80 millilitres. A family doctor writes tamsulosin 0.4 mg. And within four months, the volume goes to zero. Not reduced. Zero. He finishes and nothing comes out — because tamsulosin blocks the alpha-1A receptors that hold tension at the bladder neck, and those are the same receptors that slam the internal sphincter shut at the moment of ejaculation. Block them so urine can get past and you have blocked the valve that keeps semen going forwards. It goes backwards, into the bladder. That is a documented, expected, well-known effect of the drug. It is in the leaflet. Nobody in that man's life said it to him before he swallowed the first capsule. He just found out faster than you did, and with an audience. The 8% are different. And once I understood why they were different, I started watching for the same pattern in my non-performer patients — the executives, the agents, the producers, the directors who make up the other 40% of my practice. It was there. The men over 55 walking into my office with symptom scores of 12, 16, 19 — men whose most athletic act in a decade was a treadmill in a hotel gym — had exactly the same underlying mechanism failure as the 92% of performers who went dry, despite living lives that were gentler on that system by an order of magnitude. The enlarged-prostate patient in standard urology is treated as an age problem. The gland grows because you got older, the gland compresses the urethra, here is a capsule that relaxes the muscle around the compression so urine can get past. The protocol addresses one thing — smooth-muscle tone at the bladder neck — while the underlying mechanism continues to fail. Here is what the 8% had in common. Their prostatic and pelvic microvasculature was intact. The small vessels feeding the prostate — the capillary beds inside the gland, and the vessels running to the bladder neck and the ejaculatory ducts — were open and perfusing normally. The tissue was getting oxygen. It was not inflamed. It was not fibrosed. It was not swelling into the urethra. And the smooth muscle at that internal valve, the one that has to close on command so the ejaculate goes the right way, was getting full blood supply and doing its job. The 92% had failing prostatic microvasculature. Reduced flow into the gland. Chronically hypoxic tissue. Chronic low-grade ischemia driving inflammation, driving fibrosis, driving smooth-muscle tone. A gland that swells around the urethra and squeezes it shut a little more every year. The entire lower urinary tract was running on degraded infrastructure. And so was the valve. Most urologists treat an enlarged prostate as a growth problem. The standard model: hormones and age enlarge the gland, the gland obstructs, an alpha blocker relaxes the muscle around the obstruction. The 8% taught me that gland growth is often much less of a problem than gland perfusion. The tissue is not swelling because it is old. It is swelling because it is starving. I have spent 24 years clearing arteries for a living. Threading catheters, opening vessels, reading angiograms. Nobody in all that time ever told me one of those arteries ran to the prostate. If you restore the failing perfusion — reopen the small vessels feeding that gland and that valve — the tissue stops running a permanent inflammatory response to being suffocated. Flow improves. Residual volume drops. The nights get quieter. The mechanism that decides whether those microvessels stay open or silt shut is not hormonal and it is not age. It is a maintenance system that runs inside every blood vessel in your body, and it has a name. It is called fibrinolysis. Fibrin is the same sticky protein that scabs a cut. Your circulation lays it down constantly, in microscopic amounts, as a repair scaffold — and a crew of enzymes led by plasmin dissolves it again just as constantly. Laid down, cleared out, laid down, cleared out. That is fibrinolysis, and it runs every hour of your life without asking you. Somewhere after 50, in most men, plasmin stops showing up for work. The mesh keeps getting laid. It stops getting cleared. It silts the smallest channels first, because in a vessel that narrow there is no margin at all — and the vessels feeding a prostate are among the smallest and most pressure-sensitive plumbing you own. Now, if you are wondering why a cardiologist is telling you your prostate is a vascular organ, don't take it from me. Take it from the hospital down the road. It is called prostatic artery embolization. An interventional radiologist goes in through the wrist with a catheter, finds the arteries feeding an enlarged prostate, works on them, and the gland comes down. It is a real procedure. It is being performed in American hospitals right now. It is being advertised to men exactly like you right now — positioned explicitly on the promise that it doesn't carry the sexual cost the other operations do. There is a hospital procedure for an enlarged prostate that never touches the prostate. If the blood supply had nothing to do with this, why is there an operation aimed at it? The published pathophysiology has said the same thing for two decades. Prostatic blood flow is measurably reduced in benign prostatic hyperplasia. Chronic pelvic ischemia contributes causally to the hyperplasia itself. Reduced tissue oxygenation and vascular remodelling in the lower urinary tract are established contributors, not fringe theory. None of it made it into your eight-minute appointment. When fibrinolysis is running, the mesh gets dissolved as fast as it gets laid down. The microvessels stay open. The gland gets oxygen and does not swell. The valve gets blood and closes when it is told to. The 8% of performers over 50 who still produce full volume have a fibrinolytic system that is still turning up. Their gland is fed. Their valve works. Their plumbing absorbs a load that would finish most men in a year. When fibrinolysis goes quiet, the mesh accumulates. Flow into the gland drops. The tissue turns hypoxic, inflamed and fibrotic. It swells. It compresses the urethra. The stream weakens. The nights multiply. The bladder never fully empties. And eventually somebody writes a prescription for the muscle around the blockage — which blocks the valve at the other end, and takes the volume with it. Which is usually the point at which a man finally starts looking this up. Alone. On his phone. At eleven o'clock at night. If you are getting up two, three, four times a night — if the stream is weak and split and starts when it feels like starting — if you stand there and wait for it — if you have never once, in years, finished completely empty — then you are watching the same trajectory I watch in the 92% of my performers. And if the volume has already dropped, or already gone, you are further down that trajectory than anybody has told you. Your gland was never the enemy. It has been the casualty. The standard pathway from here runs through 0.4 milligrams, then 0.8, then a second drug added, then finasteride, and then a conversation about a catheter or an operation. I have a patient who was wearing a bag six months after his first prescription and could not understand why, because nobody had ever explained to him what the capsule was and wasn't aimed at. The enzyme that dissolves the fibrin mesh is nattokinase. It comes from natto — a fermented soybean the Japanese eat for breakfast. I laughed when one of the 8% told me what he'd been taking every morning for nine years. He was 53 at the time and out-working men half his age. Rotten beans. Fermented soybeans that smell like ammonia and pull strings like glue. That was his medical advice to a board-certified cardiologist. Everybody in my field laughed too. But the science is not a joke. 1980. Chicago. Dr. Hiroyuki Sumi, a Japanese researcher at the University of Chicago Medical School, was hunting for a natural substance that would dissolve the fibrin clots behind heart attacks and strokes. He tested 173 foods. All 173 failed. Then he dropped a lump of natto onto an artificial clot in a petri dish and left it at body temperature. The clot began to dissolve. Within 18 hours it was gone. He named the enzyme after the food. A thousand years of Japanese grandfathers had been eating the clot-dissolver for breakfast. It took a lab in Chicago and 173 failures to work out why. The human research that actually moved arterial plaque ran at 10,800 fibrinolytic units a day and reduced carotid intima-media thickness and plaque size across 1,062 participants, published in Frontiers in Cardiovascular Medicine in 2022. And the tissue side has its own literature that has nothing to do with the enzyme. Curcumin: a meta-analysis of six studies and 697 patients, with a significant reduction in prostate symptom score. Pine bark extract: 75 men aged 55 to 75, eight weeks — residual bladder volume down 51%, night-time frequency down 31%, weak flow improved 24%. Those are not my numbers. They are published, they are human, and not one of them was ever mentioned to you. The catch is the dose. And it is the catch that fooled me for the first eighteen months I recommended this to patients. Most nattokinase does nothing at all. Men came back to me after six weeks on pharmacy nattokinase capsules and reported no difference. I was confused — the mechanism was clear and the patients were textbook candidates. So I started running fibrinogen after their six weeks. It had barely moved. Nattokinase is not measured in milligrams. It is measured in FU — fibrinolytic units, a measure of actual enzyme activity, not weight. The shelf products at the pharmacy run 2,000 FU. The research that moved plaque ran at 10,800 FU a day. A man taking 2,000 FU is not taking a small dose of the right thing. He is taking a number that has never moved a marker in any trial. Below the threshold, nothing happens. You have bought a bottle of expensive beans. The 8% of performers I track had all, independently, worked this out. They were importing high-activity Japanese enzyme, or in a few cases actually eating the bean itself every single morning. Not one of them was on a drugstore 2,000 FU capsule. About 14 months ago, I found a product that does this correctly: At2a Nattokinase 10,000 FU — 7-in-1 Heart & Circulation Complex. 10,000 FU of fermented natto extract per capsule, one capsule daily, standardised and lab tested for activity per capsule. White bottle, bronze band, 30 capsules. With Vitamin K2 as MK-7 — which is the one nobody else in this category closes. You can dissolve the mesh and free the calcium that was locked up in it, and that calcium will walk straight back into the vessel wall unless something routes it into bone instead. K2-MK7 routes it. Clearing without K2 is doing half the job and calling it finished. Plus CoQ10, bromelain, turmeric, aged garlic extract, pine bark extract, grape seed and dandelion root. The turmeric and the pine bark in particular are relevant for the prostate use case — they are the two compounds carrying the human symptom-score and residual-volume trials I quoted above, and they work on the inflammation inside the tissue while the enzyme works on the mesh inside the channel. Different targets, same organ. Every prostate supplement on the shelf does the calming and ignores the plumbing. Every nattokinase product does the plumbing and has never once said the word prostate. One warning, and I mean it: not with warfarin, not with a DOAC, not on daily aspirin, and not in the weeks before surgery. If you are on a blood thinner, this is not for you, and no supplement company is going to tell you that. I take it myself. I am 51. My most recent workup: symptom score 2. Peak flow 24 millilitres a second. Post-void residual 11 millilitres. Prostate volume 26 cc. Fibrinogen 241. And because I run on myself what I run on my roster — semen volume 3.8 millilitres. I am not on tamsulosin. I am not on finasteride. I am not on Lisinopril or Amlodipine or anything like them. I sit for ten hours a day, I eat at midnight, I travel constantly, and none of that has moved those numbers out of range since I started this 14 months ago. I recommend it to my patients in three specific contexts. First, men with symptoms who have not been put on tamsulosin yet. The intervention window here is the widest it will ever be. The vessels are silting, but the tissue has not been remodelled and the valve has never been chemically interfered with. This is the group where the published tissue-layer numbers — a 4-to-6-point symptom-score reduction over 90 to 120 days — match what I see in my own charts, with no prescription anywhere in the picture. Second, men on tamsulosin alone. The window is narrower and it is still open. This runs alongside the prescription, never instead of it — do not stop a drug you were given, and do not stop it for this. The capsule keeps managing the muscle tone downstream while the enzyme works on the supply upstream. They are aimed at different things, which is exactly why they don't compete. Third, men on multiple drugs — tamsulosin plus finasteride, tamsulosin plus a blood pressure medication, or men already post-UroLift or post-TURP. The mechanism still works, because the mechanism was never about the pill. Several of my patients in this group have had their own prescriber raise the question of reducing the load over six to twelve months, under supervision, as the numbers they were actually being measured on came down. I never bring that up. Their doctor does. Here is what I want you to take from this letter. If you are a man over 50 who is up three times a night, and who has quietly noticed that the volume has dropped or gone, you are not "getting older." You are watching microvascular failure in the smallest and most pressure-sensitive plumbing you own — and it has been filing a report with you for years in the only language it has. What stopped coming out is not the disease. It is the receipt. The smallest pipes in your body report first, and they have been reporting for years while every appointment you've had looked at the gland instead. The standard approach will treat the downstream output — the stream, the frequency — with a downstream intervention, while the upstream mechanism keeps failing on schedule. And you have made a private trade you were never actually offered. Being able to piss, in exchange for being able to finish. You worked out the arithmetic on your own and you picked peeing, because that seemed like the only deal on the table. It was never the deal. Both of those things run off one set of vessels. One supply. Both outcomes. Nothing anybody has ever given you was aimed at it. The 8% of performers I track who still produce full volume in their fifties are not freaks and they are not men who take better care of themselves — several of them take considerably worse care of themselves than you do. They are men whose upstream mechanism is still running. What keeps it running is available to you, and it costs a fraction of the operation you have already priced at two o'clock in the morning. If you want to try At2a Nattokinase 10,000 FU, the official site is nt.muvost.com. One bottle is 30 days, one capsule a day. The company offers a 90-day money-back guarantee. Take it for three months. And before you start, do three things that cost you nothing. Write down how many times you get up in the night, every night, for a week. Time how many seconds it takes the stream to start. And if you can get it, ask for a symptom-score sheet and a flow study — it is a one-page questionnaire and a cup, any urologist will run it, and it gives you a number. Then do all three again at 90 days. If nothing has moved, send the bottle back, full or empty, for a full refund. I have written prescriptions for two decades. I have never once seen a pharmaceutical manufacturer offer a money-back guarantee on a prostate drug. Tamsulosin costs between four dollars eighty and nine dollars for ninety capsules and nobody stands behind it — because nobody has to. Behind it sits a benign-prostate surgical market that was worth $12.6 billion in 2024 and is on its way to $17.2 billion by 2030, and that market only opens for business on the day the capsule stops working. Nobody makes money on the pill. Everybody makes money on what comes after it. That tells you something about the difference between relaxing the muscle around a blockage and clearing the thing that caused it. The link is below. nt.muvost.com — Dr. Warren Ashby, MD Board-Certified Cardiologist, 24 years in practice Beverly Hills Concierge Medicine, 11 years Adult industry medical consultant, 11 years P.S. If you are getting up two or three times a night and the volume has dropped but has not gone to zero yet, you are in the widest intervention window you will ever have, and you are standing in it right now. The standard pathway from here is a symptom score creeping past 8, tamsulosin arriving somewhere around then, the volume gone inside four months of the first capsule, the dose doubled to 0.8 inside two years, finasteride added after that, and the catheter-or-operation conversation somewhere in the decade following. I have a patient who was wearing a bag six months in. The 8% of performers I track who still produce full volume at 55 are not men who live differently than you do — most of them live far worse. They are men whose prostatic microvasculature is still perfused, because their fibrinolytic system is still running. Yours can still be run. Somewhere in the next five to seven years the fibrosis in that tissue stops being reversible. Run the 90-day test before the 0.8 milligram conversation happens.